CoChat
Sign Up
Cited by 78Mesenchymal stem cell researchLiver physiology and pathologyLiver Disease and Transplantation

Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives

Open access
Kang, Seong Hee, Kim, Moon Young, Eom, Young Woo, Baik, Soon Koo·2020·Gut and Liver
DOI 10.5009/gnl18412PMC PMC7234888
Open this paper in CoChat — free accountOpen PDF

Abstract

Mesenchymal stem cell transplantation is an emerging therapy for treating chronic liver diseases. The potential of this treatment has been evaluated in preclinical and clinical studies. Although the mechanisms of mesenchymal stem cell transplantation are still not completely understood, accumulating evidence has revealed that their immunomodulation, differentiation, and antifibrotic properties play a crucial role in liver regeneration. The safety and therapeutic effects of mesenchymal stem cells in patients with chronic liver disease have been observed in many clinical studies. However, only modest improvements have been seen, partly because of the limited feasibility of transplanted cells at present. Here, we discuss several strategies targeted at improving viable cell engraftment and the potential challenges in the use of extracellular vesicle-based therapies for liver disease in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5009/gnl18412

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Autologous MSCs are considered a potentially clinically relevant cell type for hepatic tissue engineering due to their availability, expandability, and safety profile, along with possible beneficial immune modulation effects.

    “Autologous MSCs are considered as a potentially clinically relevant cell type for hepatic tissue engineering due to their availability, expandability, and safety profile, along with possible beneficial immune modulation effects [209,210].”

    From Liver tissue engineering using decellularized scaffolds: Current progress, challenges, and opportunities (2024) · cites this paper as [210]

    The Overview sections describe accessible, proliferative MSC sources and potentially beneficial immunomodulation; the Tissue engineering section discusses MSCs in liver scaffolds. The Present efficacy and safety section reports a small study finding autologous MSC infusion safe and feasible, but the paper does not establish the claimed combination of advantages specifically for autologous MSCs in hepatic tissue engineering. Its Conclusions also note unresolved safety risks, including carcinogenesis and viral transmission. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. [1]Shim KY Eom YW Kim MY Kang SH Baik SK 2018 Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension Korean J Intern Med 33 453 461 10.3904/kjim.2017.317 29462546 PMC5943664 · DOI
  2. [2]Kim G Kim MY Baik SK 2017 Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis Clin Mol Hepatol 23 34 41 10.3350/cmh.2016.0059 28263953 PMC5381827 · DOI
  3. [3]Kang SH Kim MY Baik SK 2018 Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon Hepatol Int 12 112 121 10.1007/s12072-017-9806-1 28698986 · DOI
  4. [4]Si-Tayeb K Noto FK Nagaoka M 2010 Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells Hepatology 51 297 305 10.1002/hep.23354 19998274 PMC2946078 · DOI · Paper page
  5. [5]Shu SN Wei L Wang JH Zhan YT Chen HS Wang Y 2004 Hepatic differentiation capability of rat bone marrow-derived mesenchymal stem cells and hematopoietic stem cells World J Gastroenterol 10 2818 2822 10.3748/wjg.v10.i19.2818 15334677 PMC4572109 · DOI
  6. [6]Kim G Eom YW Baik SK 2015 Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: systematic review and meta-analysis J Korean Med Sci 30 1405 1415 10.3346/jkms.2015.30.10.1405 26425036 PMC4575928 · DOI
  7. [7]Secunda R Vennila R Mohanashankar AM Rajasundari M Jeswanth S Surendran R 2015 Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study Cytotechnology 67 793 807 10.1007/s10616-014-9718-z 24798808 PMC4545441 · DOI
  8. [8]Ji ST Kim H Yun J Chung JS Kwon SM 2017 Promising therapeutic strategies for mesenchymal stem cell-based cardiovascular regeneration: from cell priming to tissue engineering Stem Cells Int 2017 3945403 10.1155/2017/3945403 28303152 PMC5337882 · DOI
  9. [9]Heo JS Choi SM Kim HO 2013 Neural transdifferentiation of human bone marrow mesenchymal stem cells on hydrophobic polymer-modified surface and therapeutic effects in an animal model of ischemic stroke Neuroscience 238 305 318 10.1016/j.neuroscience.2013.02.011 23454369 · DOI
  10. [10]Dominici M Le Blanc K Mueller I 2006 Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 8 315 317 10.1080/14653240600855905 16923606 · DOI · Paper page
  11. [11]Zarrabi M Mousavi SH Abroun S Sadeghi B 2014 Potential uses for cord blood mesenchymal stem cells Cell J 15 274 281 24381851 PMC3866530
  12. [12]Ribeiro A Laranjeira P Mendes S 2013 Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells Stem Cell Res Ther 4 125 10.1186/scrt336 24406104 PMC3854702 · DOI
  13. [13]Kern S Eichler H Stoeve J Klüter H Bieback K 2006 Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue Stem Cells 24 1294 1301 10.1634/stemcells.2005-0342 16410387 · DOI · Paper page
  14. [14]Liu WH Song FQ Ren LN 2015 The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases J Cell Mol Med 19 511 520 10.1111/jcmm.12482 25534251 PMC4369809 · DOI · Paper page
  15. [15]Banas A Yamamoto Y Teratani T Ochiya T 2007 Stem cell plasticity: learning from hepatogenic differentiation strategies Dev Dyn 236 3228 3241 10.1002/dvdy.21330 17907200 · DOI
  16. [16]Eom YW Shim KY Baik SK 2015 Mesenchymal stem cell therapy for liver fibrosis Korean J Intern Med 30 580 589 10.3904/kjim.2015.30.5.580 26354051 PMC4578027 · DOI · Paper page
  17. [17]Schwartz RE Reyes M Koodie L 2002 Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells J Clin Invest 109 1291 1302 10.1172/JCI0215182 12021244 PMC150983 · DOI
  18. [18]Lange C Bassler P Lioznov MV 2005 Liver-specific gene expression in mesenchymal stem cells is induced by liver cells World J Gastroenterol 11 4497 4504 10.3748/wjg.v11.i29.4497 16052678 PMC4398698 · DOI
  19. [19]Ong SY Dai H Leong KW 2006 Inducing hepatic differentiation of human mesenchymal stem cells in pellet culture Biomaterials 27 4087 4097 10.1016/j.biomaterials.2006.03.022 16616366 · DOI
  20. [20]Dai LJ Li HY Guan LX Ritchie G Zhou JX 2009 The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis Stem Cell Res 2 16 25 10.1016/j.scr.2008.07.005 19383405 · DOI
  21. [21]Kisseleva T Brenner DA 2012 The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis J Hepatol 56 965 972 10.1016/j.jhep.2011.09.021 22173163 PMC3307836 · DOI
  22. [22]Dmitrewski J Hubscher SG Mayer AD Neuberger JM 1996 Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression J Hepatol 24 253 257 10.1016/S0168-8278(96)80001-8 8778189 · DOI
  23. [23]Manousou P Arvaniti V Tsochatzis E 2010 Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity Liver Transpl 16 64 73 10.1002/lt.21960 19866449 · DOI
  24. [24]Sharma RR Pollock K Hubel A McKenna D 2014 Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices Transfusion 54 1418 1437 10.1111/trf.12421 24898458 PMC6364749 · DOI
  25. [25]Ren G Zhang L Zhao X 2008 Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide Cell Stem Cell 2 141 150 10.1016/j.stem.2007.11.014 18371435 · DOI · Paper page
  26. [26]Glennie S Soeiro I Dyson PJ Lam EW Dazzi F 2005 Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells Blood 105 2821 2827 10.1182/blood-2004-09-3696 15591115 · DOI
  27. [27]Sotiropoulou PA Perez SA Gritzapis AD Baxevanis CN Papamichail M 2006 Interactions between human mesenchymal stem cells and natural killer cells Stem Cells 24 74 85 10.1634/stemcells.2004-0359 16099998 · DOI · Paper page
  28. [28]Klyushnenkova E Mosca JD Zernetkina V 2005 T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression J Biomed Sci 12 47 57 10.1007/s11373-004-8183-7 15864738 · DOI
  29. [30]Parekkadan B van Poll D Megeed Z 2007 Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells Biochem Biophys Res Commun 363 247 252 10.1016/j.bbrc.2007.05.150 17869217 PMC2096777 · DOI
  30. [31]Wang J Bian C Liao L 2009 Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms Hepatol Res 39 1219 1228 10.1111/j.1872-034X.2009.00564.x 19788697 · DOI · Paper page
  31. [33]Chen S Xu L Lin N Pan W Hu K Xu R 2011 Activation of Notch1 signaling by marrow-derived mesenchymal stem cells through cell-cell contact inhibits proliferation of hepatic stellate cells Life Sci 89 975 981 10.1016/j.lfs.2011.10.012 22056375 · DOI
  32. [34]Semedo P Correa-Costa M Antonio Cenedeze M 2009 Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model Stem Cells 27 3063 3073 10.1002/stem.214 19750536 · DOI
  33. [35]Mohamadnejad M Alimoghaddam K Mohyeddin-Bonab M 2007 Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis Arch Iran Med 10 459 466 17903050
  34. [36]Kharaziha P Hellström PM Noorinayer B 2009 Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial Eur J Gastroenterol Hepatol 21 1199 1205 10.1097/MEG.0b013e32832a1f6c 19455046 · DOI · Paper page
  35. [37]Amer ME El-Sayed SZ El-Kheir WA 2011 Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells Eur J Gastroenterol Hepatol 23 936 941 10.1097/MEG.0b013e3283488b00 21900788 · DOI · Paper page
  36. [38]Peng L Xie DY Lin BL 2011 Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes Hepatology 54 820 828 10.1002/hep.24434 21608000 · DOI
  37. [40]Shi M Zhang Z Xu R 2012 Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients Stem Cells Transl Med 1 725 731 10.5966/sctm.2012-0034 23197664 PMC3659658 · DOI
  38. [41]Zhang Z Lin H Shi M 2012 Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients J Gastroenterol Hepatol 27 Suppl 2 112 120 10.1111/j.1440-1746.2011.07024.x 22320928 · DOI · Paper page
  39. [42]Amin MA Sabry D Rashed LA 2013 Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study Clin Transplant 27 607 612 10.1111/ctr.12179 23923970 · DOI · Paper page
  40. [43]Mohamadnejad M Alimoghaddam K Bagheri M 2013 Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis Liver Int 33 1490 1496 10.1111/liv.12228 23763455 · DOI · Paper page
  41. [44]Wang L Li J Liu H 2013 Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis J Gastroenterol Hepatol 28 Suppl 1 85 92 10.1111/jgh.12029 23855301 · DOI · Paper page
  42. [45]Jang YO Kim YJ Baik SK 2014 Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study Liver Int 34 33 41 10.1111/liv.12218 23782511 · DOI
  43. [46]Salama H Zekri AR Medhat E 2014 Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease Stem Cell Res Ther 5 70 10.1186/scrt459 24886681 PMC4097846 · DOI
  44. [47]Wang L Han Q Chen H 2014 Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis Stem Cells Dev 23 2482 2489 10.1089/scd.2013.0500 24835895 · DOI · Paper page
  45. [48]Xu L Gong Y Wang B 2014 Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells J Gastroenterol Hepatol 29 1620 1628 10.1111/jgh.12653 24942592 · DOI
  46. [50]Lanthier N Lin-Marq N Rubbia-Brandt L Clément S Goossens N Spahr L 2017 Autologous bone marrow-derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liver histology and gene expression patterns? Stem Cell Res Ther 8 88 10.1186/s13287-017-0541-2 28420441 PMC5395856 · DOI
  47. [52]Detry O Vandermeulen M Delbouille MH 2017 Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I-II, open-label, clinical study J Hepatol 67 47 55 10.1016/j.jhep.2017.03.001 28284916 · DOI · Paper page
  48. [53]Meier RP Müller YD Morel P Gonelle-Gispert C Bühler LH 2013 Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence? Stem Cell Res 11 1348 1364 10.1016/j.scr.2013.08.011 24090934 · DOI
  49. [54]di Bonzo LV Ferrero I Cravanzola C 2008 Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential Gut 57 223 231 10.1136/gut.2006.111617 17639088 · DOI
  50. [55]Salama H Zekri AR Zern M 2010 Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases Cell Transplant 19 1475 1486 10.3727/096368910X514314 20587151 · DOI
  51. [56]Mishra PJ Mishra PJ Humeniuk R 2008 Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells Cancer Res 68 4331 4339 10.1158/0008-5472.CAN-08-0943 18519693 PMC2725025 · DOI · Paper page
  52. [57]Zhou YF Bosch-Marce M Okuyama H 2006 Spontaneous transformation of cultured mouse bone marrow-derived stromal cells Cancer Res 66 10849 10854 10.1158/0008-5472.CAN-06-2146 17108121 · DOI
  53. [58]Miura M Miura Y Padilla-Nash HM 2006 Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation Stem Cells 24 1095 1103 10.1634/stemcells.2005-0403 16282438 · DOI
  54. [59]Dahl JA Duggal S Coulston N 2008 Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum Int J Dev Biol 52 1033 1042 10.1387/ijdb.082663jd 18956336 · DOI
  55. [61]Alwahsh SM Rashidi H Hay DC 2018 Liver cell therapy: is this the end of the beginning? Cell Mol Life Sci 75 1307 1324 10.1007/s00018-017-2713-8 29181772 PMC5852182 · DOI
  56. [64]Li J Tao R Wu W 2010 3D PLGA scaffolds improve differentiation and function of bone marrow mesenchymal stem cell-derived hepatocytes Stem Cells Dev 19 1427 1436 10.1089/scd.2009.0415 20055663 · DOI
  57. [65]Liu M Yang J Hu W Zhang S Wang Y 2016 Superior performance of co-cultured mesenchymal stem cells and hepatocytes in poly(lactic acid-glycolic acid) scaffolds for the treatment of acute liver failure Biomed Mater 11 015008 10.1088/1748-6041/11/1/015008 26836957 · DOI
  58. [66]Mazza G Rombouts K Rennie Hall A 2015 Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation Sci Rep 5 13079 10.1038/srep13079 26248878 PMC4528226 · DOI · Paper page
  59. [67]Deschepper M Oudina K David B 2011 Survival and function of mesenchymal stem cells (MSCs) depend on glucose to overcome exposure to long-term, severe and continuous hypoxia J Cell Mol Med 15 1505 1514 10.1111/j.1582-4934.2010.01138.x 20716129 PMC3823195 · DOI
  60. [68]Yu SP Wei Z Wei L 2013 Preconditioning strategy in stem cell transplantation therapy Transl Stroke Res 4 76 88 10.1007/s12975-012-0251-0 23914259 PMC3728897 · DOI
  61. [69]Haider H Ashraf M 2010 Preconditioning and stem cell survival J Cardiovasc Transl Res 3 89 102 10.1007/s12265-009-9161-2 20560023 · DOI
  62. [71]Qiao PF Yao L Zhang XC Li GD Wu DQ 2015 Heat shock pretreatment improves stem cell repair following ischemia-reperfusion injury via autophagy World J Gastroenterol 21 12822 12834 10.3748/wjg.v21.i45.12822 26668506 PMC4671037 · DOI
  63. [72]Sandvig I Gadjanski I Vlaski-Lafarge M 2017 Strategies to enhance implantation and survival of stem cells after their injection in ischemic neural tissue Stem Cells Dev 26 554 565 10.1089/scd.2016.0268 28103744 · DOI
  64. [73]Beegle J Lakatos K Kalomoiris S 2015 Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo Stem Cells 33 1818 1828 10.1002/stem.1976 25702874 PMC10757456 · DOI
  65. [75]Carrière A Ebrahimian TG Dehez S 2009 Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy Arterioscler Thromb Vasc Biol 29 1093 1099 10.1161/ATVBAHA.109.188318 19423864 · DOI
  66. [76]Alfaifi M Eom YW Newsome PN Baik SK 2018 Mesenchymal stromal cell therapy for liver diseases J Hepatol 68 1272 1285 10.1016/j.jhep.2018.01.030 29425678 · DOI
  67. [77]Di Rocco G Gentile A Antonini A 2010 Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging Stem Cells Int 2011 304562 10.4061/2011/304562 21234108 PMC3014681 · DOI
  68. [78]Mangi AA Noiseux N Kong D 2003 Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts Nat Med 9 1195 1201 10.1038/nm912 12910262 · DOI
  69. [79]Kutschka I Kofidis T Chen IY 2006 Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts Circulation 114 I174 I180 10.1161/CIRCULATIONAHA.105.001370 16820569 · DOI
  70. [80]Liu N Zhang Y Fan L 2011 Effects of transplantation with bone marrow-derived mesenchymal stem cells modified by Survivin on experimental stroke in rats J Transl Med 9 105 10.1186/1479-5876-9-105 21733181 PMC3146839 · DOI
  71. [81]Chen S Chen X Wu X 2017 Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats Gene Ther 24 3 11 10.1038/gt.2016.64 27556817 · DOI
  72. [82]Hu S Huang M Nguyen PK 2011 Novel microRNA prosurvival cocktail for improving engraftment and function of cardiac progenitor cell transplantation Circulation 124 S27 S34 10.1161/CIRCULATIONAHA.111.017954 21911815 PMC3181082 · DOI
  73. [83]Xu J Huang Z Lin L 2014 miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation Sci China Life Sci 57 989 997 10.1007/s11427-014-4725-z 25168379 · DOI
  74. [84]Camussi G Deregibus MC Cantaluppi V 2013 Role of stem-cell-derived microvesicles in the paracrine action of stem cells Biochem Soc Trans 41 283 287 10.1042/BST20120192 23356298 · DOI
  75. [85]Koppers-Lalic D Hogenboom MM Middeldorp JM Pegtel DM 2013 Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine Adv Drug Deliv Rev 65 348 356 10.1016/j.addr.2012.07.006 22820525 PMC7103310 · DOI
  76. [86]Kooijmans SAA Schiffelers RM Zarovni N Vago R 2016 Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: new nanotools for cancer treatment Pharmacol Res 111 487 500 10.1016/j.phrs.2016.07.006 27394168 · DOI
  77. [87]Li T Yan Y Wang B Qian H 2013 Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis Stem Cells Dev 22 845 854 10.1089/scd.2012.0395 23002959 PMC3585469 · DOI
  78. [88]Nong K Wang W Niu X 2016 Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats Cytotherapy 18 1548 1559 10.1016/j.jcyt.2016.08.002 27592404 · DOI
  79. [89]Du Y Li D Han C 2017 Exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect liver against hepatic ischemia/reperfusion injury via activating sphingosine kinase and sphingosine-1-phosphate signaling pathway Cell Physiol Biochem 43 611 625 10.1159/000480533 28934733 · DOI

Cited by

Sorted by citations

Authors
Kang, S. H., Kim, M. Y., Eom, Y. W., & Baik, S. K.
Affiliations
Yonsei University (KR)
Corresponding author
Baik, Soon Koo
ORCID
Venue
Gut and Liver
Publisher
The Editorial Office of Gut and Liver
Published
2020-05-15
Volume
14
Issue
3
Pages
306-315
ISSN
  • 1976-2283 (ISSN-L)
  • 2005-1212
DOI
10.5009/gnl18412
PMC
PMC7234888
OpenAlex
W2977610533
Cited by
78
References
10
Citations by year
2026: 5 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 18 · 2021: 15 · 2020: 4 · 2019: 1
FWCI
1.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Gut and Liver (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Research Foundation of Korea (2017R1A5A2015369, 2017R1A2B4009199, 2017R1D1A1A02019212, 2018R1C1B5044890)
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare (HI15C2364, HI17C1365)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
mesenchymal stem cells, stem cell transplantation, chronic liver disease, liver regeneration, immunomodulation, antifibrotic effect, cell differentiation, cell engraftment, extracellular vesicles, cell therapy safety
MeSH terms
Chronic Disease, Humans, Liver Diseases, Liver Regeneration, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review